OBJECTIVE: The purpose of this study was to assess whether endometrial cancer risk among long-term users of (1) sequential estrogen plus progestin 10-24 days per month exceeds that of nonusers and (2) daily estrogen plus progestin (continuous combined hormone therapy) is below that of nonusers. STUDY DESIGN: In this population-based case-control study with 1038 endometrial cancer cases diagnosed in 1985-1999 and 1453 control subjects, exclusive users of a single form of hormone therapy were compared with never users of hormone therapy. RESULTS: For sequential therapy, only long-term use (> or = 6 years) was associated with increased risk (odds ratio, 2.0; 95% CI, 1.2-3.5). Continuous combined therapy was associated with decreased risk (odds ratio, 0.59; 95% CI, 0.40-0.88), with no increased risk among long-term users (odds ratio, 0.77; 95% CI, 0.45-1.3). CONCLUSION: These results support the hypotheses that continuous combined therapy does not increase (and may decrease) endometrial cancer risk and that long-term sequential therapy can lead to a modest increased risk. However, the collective results of all studies of these questions and their clinical implications remain unclear.
OBJECTIVE: The purpose of this study was to assess whether endometrial cancer risk among long-term users of (1) sequential estrogen plus progestin 10-24 days per month exceeds that of nonusers and (2) daily estrogen plus progestin (continuous combined hormone therapy) is below that of nonusers. STUDY DESIGN: In this population-based case-control study with 1038 endometrial cancer cases diagnosed in 1985-1999 and 1453 control subjects, exclusive users of a single form of hormone therapy were compared with never users of hormone therapy. RESULTS: For sequential therapy, only long-term use (> or = 6 years) was associated with increased risk (odds ratio, 2.0; 95% CI, 1.2-3.5). Continuous combined therapy was associated with decreased risk (odds ratio, 0.59; 95% CI, 0.40-0.88), with no increased risk among long-term users (odds ratio, 0.77; 95% CI, 0.45-1.3). CONCLUSION: These results support the hypotheses that continuous combined therapy does not increase (and may decrease) endometrial cancer risk and that long-term sequential therapy can lead to a modest increased risk. However, the collective results of all studies of these questions and their clinical implications remain unclear.
Authors: Wulf H Utian; David F Archer; Gloria A Bachmann; Christopher Gallagher; Francine n Grodstein; Julia R Heiman; Victor W Henderson; Howard N Hodis; Richard H Karas; Rogerio A Lobo; JoAnn E Manson; Robert L Reid; Peter J Schmidt; Cynthia A Stuenkel Journal: Menopause Date: 2008 Jul-Aug Impact factor: 2.953
Authors: Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian Journal: J Clin Endocrinol Metab Date: 2010-06-21 Impact factor: 5.958
Authors: Britton Trabert; Nicolas Wentzensen; Hannah P Yang; Mark E Sherman; Albert R Hollenbeck; Yikyung Park; Louise A Brinton Journal: Int J Cancer Date: 2012-08-30 Impact factor: 7.396
Authors: Amanda I Phipps; Jennifer A Doherty; Lynda F Voigt; Deirdre A Hill; Shirley A A Beresford; Mary Anne Rossing; Chu Chen; Noel S Weiss Journal: Cancer Causes Control Date: 2011-09-11 Impact factor: 2.506
Authors: Anne Zeleniuch-Jacquotte; Lisa Gallicchio; Virginia Hartmuller; Kathy J Helzlsouer; Marjorie L McCullough; V Wendy Setiawan; Xiao-Ou Shu; Stephanie J Weinstein; Jocelyn M Weiss; Alan A Arslan; Immaculata De Vivo; Yu-Tang Gao; Richard B Hayes; Brian E Henderson; Ronald L Horst; Karen L Koenig; Alpa V Patel; Mark P Purdue; Kirk Snyder; Emily Steplowski; Kai Yu; Wei Zheng; Susan E Hankinson Journal: Am J Epidemiol Date: 2010-06-18 Impact factor: 4.897
Authors: Louise A Brinton; Ashley S Felix; D Scott McMeekin; William T Creasman; Mark E Sherman; David Mutch; David E Cohn; Joan L Walker; Richard G Moore; Levi S Downs; Robert A Soslow; Richard Zaino Journal: Gynecol Oncol Date: 2013-02-26 Impact factor: 5.482
Authors: Ernest K Amankwah; Christine M Friedenreich; Anthony M Magliocco; Rollin Brant; Thomas Speidel; Wahida Rahman; Linda S Cook Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-05-15 Impact factor: 4.254
Authors: Veronica Wendy Setiawan; Malcolm C Pike; Stalo Karageorgi; Sandra L Deming; Kristin Anderson; Leslie Bernstein; Louise A Brinton; Hui Cai; James R Cerhan; Wendy Cozen; Chu Chen; Jennifer Doherty; Jo L Freudenheim; Marc T Goodman; Susan E Hankinson; James V Lacey; Xiaolin Liang; Jolanta Lissowska; Lingeng Lu; Galina Lurie; Thomas Mack; Rayna K Matsuno; Susan McCann; Kirsten B Moysich; Sara H Olson; Radhai Rastogi; Timothy R Rebbeck; Harvey Risch; Kim Robien; Catherine Schairer; Xiao-Ou Shu; Amanda B Spurdle; Brian L Strom; Pamela J Thompson; Giske Ursin; Penelope M Webb; Noel S Weiss; Nicolas Wentzensen; Yong-Bing Xiang; Hannah P Yang; Herbert Yu; Pamela L Horn-Ross; Immaculata De Vivo Journal: Am J Epidemiol Date: 2012-07-23 Impact factor: 4.897